Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A4XJ
|
|||
| Former ID |
DNC001386
|
|||
| Drug Name |
SU5402
|
|||
| Synonyms |
su5402; 215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Investigative | [1] | |
| Company |
Sugen Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H16N2O3
|
|||
| Canonical SMILES |
CC1=CNC(=C1CCC(=O)O)C=C2C3=CC=CC=C3NC2=O
|
|||
| InChI |
1S/C17H16N2O3/c1-10-9-18-15(11(10)6-7-16(20)21)8-13-12-4-2-3-5-14(12)19-17(13)22/h2-5,8-9,18H,6-7H2,1H3,(H,19,22)(H,20,21)/b13-8-
|
|||
| InChIKey |
JNDVEAXZWJIOKB-JYRVWZFOSA-N
|
|||
| CAS Number |
CAS 215543-92-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7890622, 8034525, 11041561, 14800286, 26759568, 39321624, 49684200, 50917281, 53790577, 57359274, 99008168, 99437178, 99445048, 103294831, 113874309, 134340443, 134340576, 134344682, 135349716, 135610394, 135698619, 136367775, 137184213, 140077316, 143496528, 152133994, 152234912, 152258203, 152344213, 160647039, 160969610, 162011863, 162205085, 163687287, 165248398, 172919589, 174561054, 176229776, 180387005, 185969916, 187071983, 223394492, 223404372, 223554876, 223704946, 226538898, 252157173, 252160347, 252216342, 252543356
|
|||
| ChEBI ID |
CHEBI:63449
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 3 (FGFR3) | Target Info | Inhibitor | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| MicroRNAs in cancer | ||||
| Bladder cancer | ||||
| Central carbon metabolism in cancer | ||||
| Panther Pathway | FGF signaling pathway | |||
| Reactome | FGFR3 mutant receptor activation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Endochondral Ossification | ||||
| Bladder Cancer | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.